What: Combining Robotics and Machine Learning for Accelerated Drug Discovery
When: February 23, 4 PM GMT / 11 AM EST / 8 AM PST
Artificial intelligence has an increasing impact on drug discovery and development, offering opportunities to identify novel targets, hit, and lead-like compounds in accelerated timeframes. However, the success of any AI/ ML model depends on the quality of the input data, and the speed with which in silico predictions can be validated in vitro. The talk will cover laboratory automation and robotics and the benefits they offer in terms of quality and speed of data generation synergized with AI/ ML-powered drug discovery approaches.
This webinar will cover some of the general trends in the industry, and also highlight successfully implemented case studies that show how the combination of robotics and AI/ ML lead to accelerated project timelines and superior research outputs.
Martin-Immanuel Bittner, MD, DPhil, FRSA is the Chief Executive Officer of Arctoris, the drug discovery platform company that he co-founded in Oxford. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organizations, including EACR, AACR, and ESTRO. In recognition of his research achievements, he has been elected as a member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.
Ready to Get Involved?
There has never been a more important time to collaborate to innovate as an industry! If you would like to find out more about the benefits of Pistoia Alliance membership and how you can get involved with all the different initiatives we run, please send an email to Membership@PistoiaAlliance.org.